Accès ouvert
2026
article
OpenAlex
Luke Joseph Laffin, Markus Peter Schlaich, Michael E. Hall, Cathy C. Xie et autres
ABSTRACT Background Up to three-quarters of primary hypertension is epidemiologically attributed to excess adiposity. Incretin-based therapies are consistently associated with reduced blood pressure (BP) in clinical trials; however, no prior trial has investigated incretin-based therapies for hypertension treatment with BP as its …
us, au
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Shraddha Shinde, Chisom Kanu, Oralee J. Varnado, Jo Bednarik et autres
BACKGROUND: Qualitative interviews can supplement clinical trial results by providing in-depth insights into participant experiences. In the recent SURMOUNT-OSA (NCT05412004) phase III trials, tirzepatide demonstrated favorable efficacy and safety in patients with moderate-to-severe obstructive sleep apnea and obesity. To explore participants' obstructive …
us, il
(code pays fourni par la source)
2025
article
OpenAlex
L. Gyulai, Mark S. Bauer, Lauren B. Marangell, Ellen B. Dennehy et autres
OBJECTIVES: Our primary aim was to describe unique correlates of functioning in bipolar disorder (BD). EXPERIMENTAL DESIGN: The study included the first 500 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Patients were 41.9 +/- 12.7 years old, …
us
(code pays fourni par la source)
2025
article
OpenAlex
Ellen B. Dennehy, Mark S. Bauer, Roy H. Perlis, Jane Null Kogan et autres
BACKGROUND: Concordance with evidence-based guidelines in the treatment of chronic mental disorders is typically low. The study assesses the degree of concordance to recommendations of published treatment guidelines for bipolar disorder in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Potential …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Chisom Kanu, Shraddha Shinde, Sujatro Chakladar, Ellen B. Dennehy et autres
AIM: In the phase 3 SURMOUNT-OSA trials, tirzepatide treatment significantly reduced the apnea-hypopnea index (AHI) among people with moderate-to-severe obstructive sleep apnea (OSA) and obesity. We evaluated effects of tirzepatide treatment on sleep disturbance, sleep-related impairment, functioning, health-related quality of life (HRQoL), …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Urvi S. Desai, Dumingu Aparna Gomes, Julie Chandler, Wenyu Ye et autres
Recent advances in development of amyloid-targeting therapies support the potential to slow the rate of progression of Alzheimer's disease. We conducted a narrative review of published evidence identified through a targeted search of the MEDLINE and EMBASE databases (2020-2023), recent presentations at …
us
(code pays fourni par la source)
2024
article
OpenAlex
Alireza Atri, Alette M. Wessels, E Doty, Anthony S Atkins et autres
Abstract Objective To assess in Alzheimer’s disease (ad), the treatment impact of donanemab, an amyloid plaque-reducing monoclonal antibody, on readily interpretable item-measures and constructs that matter to patients, care-partners, and clinicians. Background Positive outcomes were reported from TRAILBLAZER-ALZ2, a randomised, double-blind, placebo-controlled, …
us, gb
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Davide Angioni, Jeffrey L. Cummings, C.J. Lansdall, Lavinia P. Middleton et autres
Recent positive results of three phase III anti-amyloid monoclonal antibody trials are transforming the landscape of disease-modifying therapeutics for Alzheimer's disease, following several decades of failures. Indeed, all three trials have met their primary endpoints. However, the absolute size of the benefit …
fr
(code pays fourni par la source)
2024
article
OpenAlex
Alireza Atri, Alette M. Wessels, Erin Gautier Doty, Alexandra S. Atkins et autres
To assess in Alzheimer’s disease (AD), the treatment impact of donanemab, an amyloid plaque-reducing monoclonal antibody, on readily interpretable item-measures and constructs that matter to patients, care-partners, and clinicians1–3.
us, sg
(code pays fourni par la source)
2024
article
OpenAlex
Mark A. Mintun, Craig Ritchie, Paul R. Solomon, John Randall Sims et autres
Abstract Introduction In TRAILBLAZER-ALZ donanemab (DONA) cleared brain amyloid plaques, significantly slowing disease progression in early symptomatic Alzheimer’s disease (ESAD). Methods: TRAILBLAZER-ALZ2 enrolled participants with ESAD and amyloid and tau pathology by positron-emission tomography, randomizing (multicenter) those with low/medium-tau (n=1182) and high-tau …
us, se
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Mark A. Mintun, Craig Ritchie, Paul R. Solomon, John Randall Sims et autres
Abstract Background In TRAILBLAZER‐ALZ, donanemab cleared brain amyloid plaques and significantly slowed disease progression in early symptomatic Alzheimer’s disease (AD). Methods TRAILBLAZER‐ALZ 2 (NCT04437511), a multicenter, randomized, double‐blind, placebo‐controlled trial, enrolled participants with early symptomatic AD and amyloid and tau pathology by …
us, se
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Julie Chandler, Wenyu Ye, Xiaojuan Mi, Ellen B. Dennehy et autres
Abstract Background Associations between disease progression (DP) and health outcomes are poorly characterized in mild cognitive impairment (MCI) and mild AD (MILD). To address this, we examined the impact of DP on incremental changes in independent functioning over 18 months; baseline factors …
us
(code pays fourni par la source)